Kimberly-Clark gets fresh Barclays target, shares sit in S&P 500 consumer mix

Barclays nudges its Kimberly-Clark price target to 101 dollars while holding an Equalweight stance, keeping the tissue and hygiene group in line with a broadly cautious view on S&P 500 consumer staples valuations.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 20:54.

Kimberly-Clark (US4943681035) stays on analysts' radar on the NYSE after a fresh valuation tweak from Barclays. The London-based house adjusted its price target while keeping an Equalweight view on the S&P 500 consumer staples name, according to a Marketscreener summary published on 2026-06-23. Marketscreener note on the Barclays update

What Barclays is signaling

Barclays now sets its Kimberly-Clark price target at 101 US dollars, up from 99 dollars previously, and reiterates an Equalweight rating, as reported in Tuesday's brief. The Marketscreener Barclays recap places the move in a context where the shares last closed around 100.50 dollars, implying only limited upside versus that target.

Alongside Barclays, other houses such as Piper Sandler have recently taken a more constructive stance, with Piper Sandler in mid-June lifting its Kimberly-Clark target to 121 dollars and maintaining an Overweight rating, according to the same aggregation. Marketscreener consensus data for Kimberly-Clark currently show an average analyst target around the mid-110s in dollars, leaving a double-digit percentage gap to the present share price.

Consensus picture and index context

MarketBeat lists Kimberly-Clark with an average broker recommendation of "Hold", based on a mix of Hold and Buy ratings from firms including Goldman Sachs and JPMorgan, with very few outright Sell calls. MarketBeat overview on Kimberly-Clark also puts the average 12-month price objective in the low- to mid-110-dollar range, broadly in line with Marketscreener's figures.

Within the S&P 500 consumer staples space, Kimberly-Clark trades alongside peers such as Procter & Gamble and Colgate-Palmolive, positioning it in a defensive segment that has seen muted valuation expansion compared with growth-oriented technology names this year. Recent MarketBeat data show the shares changing hands a little above 100 dollars, leaving the stock on a forward price-earnings multiple that sits at a discount to some larger staples peers, but above more value-oriented names in food and beverages. MarketBeat analyst research page for Kimberly-Clark

How Kimberly-Clark earns its money

Kimberly-Clark generates the bulk of its revenue from branded tissue, diaper and personal-care products, with Huggies diapers, Kleenex tissues and Cottonelle bathroom tissue among its most recognizable franchises. According to company presentations on its Powering Care strategy, the group has achieved nine consecutive quarters of volume and market-share growth, supported by a push to premiumize key brands and expand in emerging markets such as Brazil, Indonesia, Vietnam and Korea. Yahoo Finance summary of Kimberly-Clark's dbAccess conference remarks

Where the Kimberly-Clark shares trade

The Kimberly-Clark shares (US4943681035) last closed on the NYSE at 100.50 US dollars on 2026-06-22 at 16:00 Eastern Time, implying a market capitalization of around 33 billion dollars based on exchange data collated by German portal finanzen100.

Key data on the Kimberly-Clark shares

• Company: Kimberly-Clark Corporation
• ISIN: US4943681035
• WKN: 855178
• Ticker: KMB
• Trading venue: NYSE
• Price (as of 2026-06-22, 16:00): 100.50 USD
• Market cap: around 33 billion USD (as of 2026-06-22)
• Sector / industry: Consumer Staples / Household & Personal Products
• Index membership: S&P 500
• Next earnings date: 2026-07-22

This article is for informational purposes only and does not constitute investment advice, investment recommendation or an invitation to buy or sell securities. Every investment in the capital markets is subject to risks up to and including total loss. Investors should conduct their own research or consult a professional advisor before making investment decisions.